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Background: One of the most important measures for ascertaining the impact of tobacco is the estimation of the
mortality attributable to its use. Several indirect methods of quantification are available. The objective of the article
is to assess methodologies published and applied in calculating mortality attributable to smoking.
Methods: A review of the literature was made for the period 1998 to 2005, in the electronic databases MEDLINE.
Twelve articles were selected for analysis.
Results: The most widely used methods were the prevalence methods, followed by smoking impact ration method.
Ezzati and Lopez showed that the general rate of Smoking attributable mortality (SAM) globally was 12% (18% in men).
Across countries, attributable fractions of total adult deaths ranged from 8% in Southern Africa, 13.6% in Brazil (18.1% in
men) and 25% in Hong Kong (33% in men).
Conclusion: The variations can be attributed to methodological differences and to different estimates of the main
tobacco-related illnesses and tobacco prevalence. All methods show limitations of one type or another, yet there is
no consensus as to which furnishes the best information.
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Non-communicable diseases are rapidly increasing in
many developing countries, largely due to demographic
and lifestyle changes. It is estimated that nearly half the
disease burden in low and middle-income countries
(LMIC) is from non-communicable diseases, and more
than 21% of deaths in such countries are due to cardio-
vascular diseases [1]. Globally, many of the risk factors
for heart disease, diabetes, cancer and pulmonary dis-
eases are due to lifestyle and can be prevented.
Among risk factors for non-communicable diseases,
tobacco is enemy number one [2]. It is a widely estab-
lished cause of cancer, and moreover, also responsible
for cardiovascular and chronic respiratory diseases. The
growth in smoking rates is followed ten to twenty years
later by the increase in the incidence of diseases such as
ischemic heart disease, lung, oral cavity and larynx can-
cers; and 20 to 40 years later, by chronic obstructive* Correspondence: Tachfoutinabil@yahoo.fr
1University of Bordeaux, Bordeaux, France
4Laboratory of Epidemiology, Clinical Research and Community Health
-Faculty of Medicine, KM: 2.2 Route de Sidi Harazem, Fez, Morocco
Full list of author information is available at the end of the article
© 2014 Tachfouti et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.airway disease [3,4]. Tobacco impact on society can be
measured in terms of the mortality burden, which repre-
sents tobacco-attributable deaths [5].
It has been estimated that there are more than 1.3 bil-
lion smokers worldwide, with around 82% residing in
LMIC [6]. Eighty five percent of the world’s population
lives in LMIC [7]. 10% of all deaths resulting from non-
communicable diseases (including cancer, cardiovascular,
chronic respiratory diseases, and diabetes) are related to
tobacco and most of these occur in these countries [8].
In people over age 30, smoking accounts for one in every
five deaths among men and one in every 20 deaths among
women globally [9]. The World Health Organization
(WHO) has estimated that approximately 5.4 million
people died worldwide from tobacco-related illnesses in
2006 [10]. Unless urgent action is taken, tobacco’s annual
death toll will rise to more than eight million by the year
2030. More than 80% of those deaths will be in LMIC
[10]. Over five million of these deaths are attributed dir-
ectly to smoking, and about 600,000 to second hand
smoke [11], people who they do not smoke but breathe
air polluted by poisonous gases from those who smoke. Ital Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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attributable deaths will decrease by 9% in developed
countries, but increase by 100% (to 6.8 million) in develop-
ing countries [12].
Ezzati et al. [13] estimated that 11% of all cardio-
vascular deaths in the world in 2000 could be attrib-
uted to tobacco, in particular ischemic heart disease and
cerebrovascular disease [14]. In addition, cancer has been
attributed to 21% of all cancer deaths in the world, in-
cluding 29% of deaths in developed countries and 18% in
developing countries [15]. The UK prospective study of
smoking and death among British doctors that began in
1951 found that men born in 1900–1930 who smoked
only cigarettes and continued smoking died on average
about 10 years younger than lifelong non-smokers. Ces-
sation at age 60, 50, 40, or 30 years gained, respectively,
about 3, 6, 9, or 10 years of life expectancy [16].
Although the negative effects of smoking on mortality
at the individual level are well established, measuring
the mortality impact at the population level is more
challenging because of the difficulty of obtaining accur-
ate cohort histories of smoking behavior. Cohort data
are necessary because smoking generally begins rela-
tively early in life, whereas the full impact on mortality
is not revealed until at much older ages [17]. The most
persuasive evidence identifying the mortality risks asso-
ciated with smoking has been drawn from prospective
cohort studies that compare the death rates of current
smokers and former smokers with the death rates of
those who never smoked regularly. The Cancer Prevention
Study II (CPS-II) in the USA is the largest such study, but
is based on a sample of volunteers who are more likely to
be White, middle class and college-educated than the
US population as a whole [18].
Smoking attributable mortality (SAM) has been widely
used in studies and is considered to be one of the most
relevant summary statistics. Due to its capacity to show
the harm that tobacco causes to health, it would be of
help in the planning of health policy. The task of quanti-
fying SAM has been performed mainly through indirect
methods. This review sought to describe the different
methods of estimating mortality attributed to tobacco
use, to indicate the principal finding and methodological
differences existing among them.
Methods
In order to obtain papers that addressed the method-
ology employed for attributing mortality to tobacco use,
a review of the MEDLINE electronic databases was car-
ried out in January 2013 for the period 1998 to 2005.
Search terms were used, including “attributable risk”,
“mortality”, “smoking”, in combination with the key
words “tobacco”. The search was completed with a man-
ual review of the bibliographic references cited by thepapers retrieved and of other publications, such as the
monographs published by the Centers for Disease Con-
trol and Prevention (CDC) concerning data about SAM
in Canada, USA and Portugal.
The main inclusion criterion was the use of modelling
to estimate attributable mortality. Papers merely describ-
ing mortality, such as cohort follow-up or mortality
studies were excluded. Articles published in English,
were included; those in other languages were excluded
irrespective of whether they contained a summary in
English. No restriction was taken into account on loca-
tion of publication or period of the study.
A total of 186 articles were found, 30 of which were
selected since they used modelling methods to estimate
tobacco attributable risk. Eighteen papers were excluded
since they used an age range < 25 years. As a result, 12
articles published between 1998 and 2005 were included
in the analysis.
The following items were extracted from the chosen
articles: authors, location where the study was carried
out, publication year, age range of the population under
study, way of calculating the SAM, main findings and
limitations or problems identified.
Results and discussion
Type of models and used methods
Smoking attributable mortality (SAM) has been used in
studies in the form SAM%, giving the proportion of all
deaths in general or of those with a specific cause that
are attributable to tobacco. The applied methodology in
these studies can be classified under three categories:
prevalence-based analysis in cohort studies (SAMMEC
method), prevalence-based analysis in case–control studies,
smoking impact ratio method. The methods differ in
terms of calculation processes, information require-
ment, data sources and assumptions required for their
application. Table 1 shows the results of the articles, by
year, location of publication, method of calculating the
SAM and age range under analysis. The main charac-
teristics of the different indirect methods are described
below.
Prevalence-based analysis in cohort studies (SAMMEC)
This method is the most commonly employed in the lit-
erature [19-26]. Attributable deaths are calculated for
each cause of mortality using the following formula:
AM =OM× PAF; where AM is the mortality attributed
to a specific factor (SAM in the case of smoking), OM
the observed mortality, and PAF the population attrib-
utable fraction. The first step consists in selecting the
most relevant smoking related pathologies for which re-
liable data are available. These pathologies and their co-
dification in two International Disease Classifications,
ICD 9, Clinical Revised Modification, and ICD 10, are
Table 1 Methods used in calculating the Smoking Attributable Mortality (SAM) by location and date of study
Ref Location/ Year of study Method used Age range Source of data
[21] Canada, 2001 SAMMEC >35 Canadian community health survey;
Mortality registry
[22] Brezil, 2003 SAMMEC >35 Brazilian mortality system;
Household survey on NCD risk factors
[23] Israel 2003 SAMMEC >35 National smoking prevalence data;
National mortality data survey
[24] Portugal 2005 SAMMEC >35 National heath enquiries
[25] USA, 2005 SAMMEC >35 National center for health statistics’ and US mortality data
[26] Taiwan, 2001 SAMMEC >30 National health interview survey;
Official projection of number of deaths
[35] China, 1998 Case >40 Official death certificates;
Disease surveillance points
[33] India 2003 Case >25 Case control survey among mal
[34] Hong kong 2004 Case >35 Death registry
[37] South Africa 2004 Case >35 The South African death notification system
[40] World 2003 SIR >30 WHO GB database
[13] World 2005 SIR >30 WHO GB database cardiovascular
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quantitative relationship between smoking and the se-
lected pathologies.
In order to do that, we used epidemiological con-
cepts of relative risk and population attributable risk.
Relative risk (RR) is the ratio between the risk of a
disease or death for a population exposed to smoking
and this risk for a non-exposed population. To calcu-
late PAF, different methods exist [28], the most widely
method used is based on the formula proposed by Levin
[29] which divides the population into various categories
according to tobacco use (non-smokers, ex-smokers and
smokers):
PAF ¼ p0þ p1 RR1þ p2 RR2ð Þ−1ð Þ
= p0þ p1 RR1þ p2 RR2ð Þ;
where p0, p1 and p2 represent the prevalence of non-
smokers, smokers and ex-smokers, respectively. Data are
drawn from registries in the case of observed mortality
and from surveys in the case of smoking prevalence.
RR1 and RR2 refer to the risk of dying for smoking re-
lated pathologies of smokers and ex-smokers respect-
ively compared to a baseline population of non-smokers.
The relative risks (RRs) employed in the calculations are
extracted mainly from the prospective cohort study con-
ducted by the American Cancer Society, i.e., the Cancer
Prevention Study II (CPS II) [30,31]. PAF is estimated
for the 22 tobacco related diseases [32]. The CDC’s
SAMMEC (Smoking-Attributable Mortality, Morbidity,and Economic Cost) computer software application [32]
uses this methodology. SAMMEC is a software package
commonly used in the United States to estimate attribut-
able mortality due to smoking, years of potential life lost
and indirect mortality costs.
Prevalence-based analysis in case–control studies
Employing a similar calculation procedure to the previ-
ous method, this one emerged as a consequence of the
objections raised by certain researchers about using RRs
to estimate smoking attributable mortality from other
countries [33,34]. This method has been used to estimate
mortality attributable to tobacco use in China when the
epidemic was still in the initial phase [35,36] and South
Africa [37]. To apply this method, it is necessary to know
the total deaths for all causes among subjects aged 35 years
or more for a given period of time.
By interviewing survivors, information is collected
retrospectively on smoking habits of deceased subjects
15 years before their death. Based on a case–control
study risks are estimated. Once these risks obtained, the
population attributable fraction (PAF) can then be calcu-
lated, applying the formula:
PAF ¼ P 1− 1=RRð Þð Þ;
where P is the proportion of deaths occurring among
smokers and RR the relative risk calculated as OR
after completion of a case–control study. When the
PAF has been calculated, deaths attributed to tobacco
Table 2 ICD 9-CM and ICD 10 codes for smoking related
diseases
Malignant cancers ICD 9 - CM ICD 10





Lips, oral cavity, pharynx 140-149 C00 – C14
Neck of the uterus 180 C53
Kidney, renal pelvis 189.1 C64-C65
Urinary bladder 188 C67
Acute myeloid leukaemia 205 C92.0
Cardiovascular diseases
Ischemic heart disease
<65 years 410-414 I20-I25
>65 years
Cerebrovascular disease
<65 years 433-434 I63 – I69
>65 years 436-438
Atherosclerosis 440 I 70
Aortic anevrysm 171.9 I71
Other arterial disease 440-448 I72-I78
Other cardiac diseases 412-414 I25
Respiratory diseases
Bronchitis, emphysema 490-492 J40-J43
Chronic airway obstruction 496 J44 – J46
Pneumonia, influenza 480-487 J10-J18
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as follows:
AM ¼ OM  PAF :
Smoking impact ratio method
To capture the accumulated hazard of smoking, the SIR-
method (smoking impact ratio) was elaborated by
Peto et al., that is adapted to the specific conditions
of developing countries [38-40]. The method uses lung
cancer mortality data, which are available or can be es-
timated using various methods, as an indirect indica-
tor of the accumulated hazards of tobacco smoking.
Background-adjusted SIR is defined as population lung
cancer mortality in excess of never-smokers relative to
excess lung cancer mortality for a known reference
group of smokers, adjusted to account for differences
in never-smoker lung cancer mortality rates across
populations [41,13].This model may estimate mortality independently of
the prevalence of smoking in the study population. To
apply this method, one needs to know the age- and sex-
specific lung cancer mortality rates in the target country
(CLC) and also in never-smokers of the same population
(NLC), the relative risks for all diseases and disorders
causally related to tobacco, except lung cancer; and the
cause-specific lung cancer mortality rates in smokers
(S*LC) and never smokers (N*LC), taken from a cohort
study. Peto et al. used data drawn from the CPS II. SIR
is calculated by age and sex. Age groups were 30–44,
45–59, 60–69, 70–79 and ≥80. No deaths before the age
of 30 were attributed to smoking because there are few
cancer deaths before 30 and RRs are unstable.
The second step of this process consists of computing
the population etiological fraction (PEF) on the basis of
the previously calculated summarized prevalence (SIR)
and the relative risks of dying due to the respective
causes (RR), by age group and sexx as per the CPS II.
PEF ¼ SIR RR−1ð Þ= 1þ SIR RR−1ð Þð Þ:ð
The last step in this procedure would involve applying
the following formula: AM =OM × PEF, in order to ob-
tain the estimation of attributed mortality, AM, in ac-
cordance with the PEF previously calculated and the
observed mortality, OM.
Smoking attributable mortality
Table 3 presents the principle findings and general char-
acteristics of the studies. The studies were organized ac-
cording to the methods used for calculating the SAM.
Most studies used the relative risk (RR) from CPS II.
Smoking related pediatric illnesses, deaths caused by to
passive smoking and tobacco related fires were not in-
cluded in the most studies analyzed here with some
exceptions [42]. Most studies using prevalence based
methods used an age range >35 years for the calculation
of the SAM, with some exceptions [26,33,36]. Studies
using Peto’s method used age rage >30 years.
Ezzati and Lopez showed that the general rate of SAM
globally was 12%; 18% among men and 5% among women.
Lung cancer was the disease with the highest fraction at-
tributable to smoking. 71% of all lung cancers or 0 · 85
million deaths (79% or 0 · 69 million deaths among men
and 48% or 0 · 16 million deaths among women) were at-
tributable to smoking. In the year 2000, 11% of total global
cardiovascular deaths, were due to smoking; 17% for men
and 5% for women [39]. SAM represented 9% of total
adult mortality in developing countries where it repre-
sented 14% of total mortality in adult men (2 · 02 million
deaths) and 3% of total mortality in women (380 000
deaths). In these countries, SAM represented 65% of lung
cancer deaths in men aged between 30 and 69 years and
Table 3 Summary of Smoking Attributable Mortality (SAM) as reported in the articles included in the review
SAM in thousands of deaths (proportion of total adult mortality) Comments
Ref Male Female Both
[19] 27.600 (26.2%) 13.170 (13.4%) 40.770 (20.0%) SAM as a rate of total death;
[22] 16.896 (18.1%) 7.326 (8.1%) 24.222 (13.6%) Mortality estimation according to smoking related disease group
in 16 Brazilians cities
[23] 3.680 2595 6.275 (16.3%) Use of the lagged SAMMEC models
[24] 9.890 (17.8%) 2.725 (5.2%) 12.615 (11.7%) Estimation of other tobacco burdens (Dalys, deaths…)
[25] 259.5 178.5 438 Estimation of annual deaths between1997 and 2001, inclusion of
second hand smoking death
[26] 16.123 (22.2%) 2.680 (5.9%) 18.803 (16.0%) Take into consideration induction time.
[32] 500 (13%) 100 (3%) 600 (12%) Estimation of future burden under scenarios of health promotion
[33] - - 550 Estimation of men deaths only
[36] 2.534 33% 0.169 (5%) 2701 (25%) Graphic form of data
[34] - - 20000 (8%) Deaths estimation by cause: lung cancer, COPD, tuberculosis and
vascular deaths.
[38] 2410 (14%) 380 (3%) 2020 (9%) Assumes constant worldwide lung cancer mortality rates among
never smokers.
Worldwide use.
[13] - - 670 (7%) Estimation of cardio vascular deaths
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[13]. In the studies assessed here, the general SAM was
between 8% in Southern Africa and 25% in Hong Kong; in
Brazil, it represents 13.6% of total deaths [34,24,22]. In
men, the rate was between 13% in China, 18.1% in Brazil
and 33% in Hong Kong and in women between 3% in
China, 8.7% in Brazil and 13.4% in Canada. In Southern
Africa, 58% of lung cancer mortality was attributable
to tobacco (61% in males and 48% in females). Smok-
ing caused 18% of ischemic heart diseases death.
Smoking caused 30.2% and 29.1% of cancer mortality
respectively in Brazil and Israel. It is responsible for
32.4% and 42.6% of cardiovascular mortality in the
same countries [22,23].
Discussion
Our review shows that mortality from smoking varied
greatly among different countries (from 8% in South
Africa to 25% in Hong Kong). SAM is highly concen-
trated among men (33% in Hong Kong and 22.2% in
Taiwan) [34,26]. A comparison between the results that
Ezzati and Lopez [40] and Ezzati et al. [41] reported for
SAM% with those from studies that use a more uniform
methodology [25] shows that the general mortality rate
(18% - 23%) was higher for the world and for developed
countries in the former studies.
Although it is very difficult to generalize about devel-
oping countries as there are huge variations in the smoking
epidemic determined by diverse demographics and eco-
nomic and cultural determinants. First, mortality attribut-
able to smoking in these regions is highly concentratedamong men (84% of smoking-attributable deaths). Smok-
ing killed three times as many men as women in indus-
trialized countries and almost seven times as many in
developing countries. Second, compared with industrial-
ized countries, developing countries have a higher pro-
portion of SAM at age 30 to 69 (62% in less-developed
countries, compared with 49% in industrialized nations)
[41]. The tobacco related illnesses that most contribute
towards the SAM in developing countries were cancer
of the trachea/ bronchial/ lungs, ischemic heart disease,
COPD and cerebrovascular diseases [26,36]. Ezzati and
Lopez also found cardiovascular disease, COPD and
lung cancer to be the three principal causes of smoking
related deaths in developed and developing countries in
the year 2000 [42].
The first limitation affecting comparison of the cited
studies stems from the use of a different methodological
approach in the various studies. The studies reviewed
here are quite heterogeneous in many aspects: the
method for calculating the attributable fraction, the in-
clusion or not of certain tobacco-related diseases in
adults or children, the age range considered, the inclu-
sion of death by burning, passive smoking and the appli-
cation of the current prevalence to calculate the SAM.
All these factors influence the results of the attributable
mortality. The second limitation resides in the absence
of a universal definition of the categorization of tobacco
use. To view smokers as a single entity could lead to a
distorted mortality estimate, since failure to take account
of the number of cigarettes smoked, age at initiation and
years of smoking [42,43].
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based methods, centers on their reliance on current
smoking prevalence’s to reflect mortality occasioned by
tobacco use in previous years. Knowing current smoking
prevalence could be a great help when it comes to pre-
dicting future mortality, it might fail however with re-
spect to the present mortality [43]. The use of current
prevalence may overestimate or underestimate the at-
tributable mortality. In countries where the prevalence is
decreasing, the use of current prevalence is conservative
in the proportional attribution method. In Israel, where
tobacco use has been decreasing for several decades,
using a lagged approach – which took into account the
fact that smoking rates between 1959 and 2003 contrib-
ute to SAM in 2003, due to lag factors - produced a
SAM overestimate of 50% on the SAMMEC categories
[23].The opposite in countries where prevalence is in-
creasing. As yet, this problem has no easy solution, due
to the absence of historical series of smoking prevalence
in most countries.
Peto et al. avoided the problem entailed in prevalence
dependent methods of attribution. For the application of
their estimation procedure, lacks of knowledge of the to-
bacco consumption or latency and induction periods are
no limitations. Smoking impact ratio method defined
synthetic prevalence as an indicator that summarizes a
population’s smoking history, and calculate it by assum-
ing CPS II data on lung cancer mortality rates among
smokers and non-smokers to be valid. The use of these
two sets of data gave rise to numerous criticisms espe-
cially representativeness of the CPS population. Most of
the population included in this cohort study was middle
class, which may result in lung cancer mortality in non-
smokers being underestimated, which in turn may lead
to an overestimation of lung cancer mortality attribut-
able to tobacco use and, by extension, to an overesti-
mation of the summarized prevalence [44-46].
Possibilities of confounding are also not properly taken
into account by the fact that smoker/nonsmoker relative
risks for diseases other than lung cancer are estimated
from unadjusted CPS II data and assumed to apply to
countries with a very different distribution of risk factor
exposure than the CPS II population, a population which
is not even representative of the United States. The
method implausibly assumes that lung cancer rates in
lifelong nonsmokers do not vary by country and by year,
thus ignoring possible diseases are unlikely to be repre-
sentative, in terms of effects of other risk factors [47].
The fourth limitation centers on the absence of world-
wide risk indicators that would reflect the degree of as-
sociation between tobacco and smoking related-causes
of mortality. Although drawn from different sources, the
RRs used in the various studies mainly came from the
CPS II [30,31]. Applying these risks to populations otherthan that of the USA aroused criticism. A solution to
these problems was sought through a re-analysis of the
data [48,49], and the RRs were shown robust. The ab-
sence of a simulation study involving and comparing all
calculations procedures do not allow us to recommend a
method over other one. Data availability should be taken
into account when choosing a method. These types of
methods furnish estimates that constitute valuable infor-
mation and help forming a more accurate picture of the
problem that smoking poses to world health.Conclusion
This analysis of different studies has shown the powerful
impact that tobacco consumption has on the mortality
of populations. Many low- and middle-income countries
are still in early stages of the tobacco epidemic. In these
nations, smoking attributable mortality is low compared
to developed countries. In view of the expected demo-
graphic and epidemiological transitions and of current
smoking patterns in these counties, the health loss due
to smoking will grow even larger unless effective inter-
ventions and policies that reduce smoking among men
and prevent increases among women are implemented.
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